Fiona M. Miall

Leicester, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Coronavirus disease 2019 (COVID-19) risk and evolving treatment patterns in follicular lymphoma during the pandemic: Insights from the PETReA trial.

Coronavirus disease 2019 (COVID-19) risk and evolving treatment patterns in follicular lymphoma during the pandemic: Insights from the PETReA trial.

Journal: British journal of haematology

Published: February 18, 2026

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Journal: Blood advances

Published: February 05, 2026

Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses.

Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses.

Journal: Blood advances

Published: February 05, 2026

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.

Journal: Blood

Published: February 18, 2025

Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial.

Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial.

Journal: The Lancet. Haematology

Published: November 12, 2024

Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful-waiting.

Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful-waiting.

Journal: British journal of haematology

Published: July 28, 2024

Specialised foundation programme allocation: making research everyone's business.

Specialised foundation programme allocation: making research everyone's business.

Journal: BMJ (Clinical research ed.)

Published: April 08, 2024

Neoadjuvant Immunotherapy and De-escalation of Surgery in Locally Advanced Breast Implant-associated Anaplastic Large Cell Lymphoma.

Neoadjuvant Immunotherapy and De-escalation of Surgery in Locally Advanced Breast Implant-associated Anaplastic Large Cell Lymphoma.

Journal: Archives of plastic surgery

Published: October 02, 2023

Towards an empathic hidden curriculum in medical school: A roadmap.

Towards an empathic hidden curriculum in medical school: A roadmap.

Journal: Journal of evaluation in clinical practice

Published: August 29, 2023

Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.

Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.

Journal: The Lancet. Haematology

Published: August 22, 2023

Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience.

Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience.

Journal: Blood advances

Published: July 26, 2023

Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study.

Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study.

Journal: Blood advances

Published: July 14, 2023

Showing 1-12 of 27

Last Updated: 09/26/2026